Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial

Heterologous and fractional dose COVID-19 vaccine schedules in adolescents are safe, well-tolerated and immunogenic. The enhanced performance of the heterologous schedule using NVX-CoV2373 against the Omicron SARS-CoV-2 variant suggests this mRNA prime and protein-subunit boost schedule may provide a greater breadth of protection than the licensed homologous schedule.

Source: Journal of Infection - June 16, 2023 Category: Infectious Diseases Authors: Eimear Kelly, Melanie Greenland, Philip C S de Whalley, Parvinder K Aley, Emma L Plested, Nisha Singh, Stanislava Koleva, Sharon Tonner, Grace C Macaulay, Robert C Read, Mary Ramsay, J Claire Cameron, David P J Turner, Paul T Heath, Jolanta Bernatoniene, Source Type: research